ABCG2 and colorectal carcinoma: Importantly, one of the mechanisms of resistance to irinotecan in CRC is that ABCG2 gene encodes ABC efflux transporter and reduces intracellular drug accumulation [109], so targeting ABCG2 is an effective therapeutic principle to enhance the efficacy of irinotecan [110].